Published in final edited form as:

Cancer Epidemiol. 2018 August ; 55: 68–72. doi:10.1016/j.canep.2018.05.007.

Testicular cancer among US men aged 50 years and older

Armen A. Ghazarian^{a,b,1}, Carsten Rusner^{c,1}, Britton Trabert^a, Megan Braunlin^a, Katherine A. McGlynn^{a,*}, Andreas Stang^{d,e,f}

^aDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA

^bDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA

^cDepartment of Radiology, St. Elisabeth and St. Barbara Hospital, Halle (Saale), Germany

^dCenter of Clinical Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany

^eDepartment of Epidemiology, School of Public Health, Boston University, Boston, MA, USA

^fGerman Consortium of Translational Cancer Research (DKTK), Partner Site University Hospital of Essen, University of Duisburg-Essen, Essen, Germany

Abstract

Background: The incidence of testicular cancer in the United States (US) has substantially increased in recent decades. The majority of testicular cancers are germ cell tumors (TGCT), which are the most commonly occurring malignancies among men aged 15–44 years in the US. To date, few studies have focused on testicular cancer among men aged 50 years. Thus, we sought to examine detailed descriptive features, including incidence rates and age patterns, of tumors that arise in the testes among men aged 50 years.

Methods: Data from forty-one US cancer registries were included for the years 1999–2014. Incidence rates per 100,000 person-years and their 95% confidence intervals (CI) were calculated by race/ethnicity, histology, and age at diagnosis. Estimates of annual percent change (APC) were also calculated.

*Corresponding author at: National Cancer Institute, 9609 Medical Center Drive, Room 6E-446, Bethesda, MD, 20892, USA. mcglynnk@mail.nih.gov, mcglynnk@nih.gov (K.A. McGlynn).

¹These authors contributed jointly to the manuscript.

Author contributions

Armen A. Ghazarian: Conceptualization, methodology, software, formal analysis, investigation, data curation, writing–original draft, writing–review and editing, and visualization.

Carsten Rusner: Conceptualization, methodology, software, formal analysis, investigation, data curation, writing–original draft, writing–review and editing, and visualization.

Britton Trabert: Conceptualization, methodology, software, formal analysis, data curation, and writing–review and editing.

Megan Braunlin: Software, validation, formal analysis, data curation, writing–review and editing.

Katherine A. McGlynn: Conceptualization, methodology, validation, formal analysis, writing–review and editing, and supervision.

Andreas Stang: Conceptualization, methodology, validation, formal analysis, writing–review and editing, and supervision.

Conflicts of interest

The authors declare no competing interests and have no financial disclosures.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.canep.2018.05.007>.

Results: Age-specific incidence rates of spermatocytic tumors, sex cord stromal tumors and lymphomas rose with age, while age-specific incidence rates of seminomas and nonseminomas declined. Between 1999 and 2014, the incidence of nonseminoma (APC = 3.26, 95% CI: 2.27–4.25) increased more than any other tumor type. The incidence of seminoma (APC: 1.15, 95% CI: 0.59–1.71) also increased, while rates of testicular lymphoma (APC: –0.66, 95% CI: –1.16 to –0.16), spermatocytic tumors (APC: 0.42, 95% CI: –1.42 to 2.29), and sex cord stromal tumors (APC: 0.60, 95% CI: –3.21 to 4.55) remained relatively unchanged.

Conclusion: Given the distinct time-trends and age-specific patterns of testicular cancer in men aged 50 years, additional investigation of risk factors for these tumors is warranted.

Keywords

Testicular cancer; TGCT; Trends; NAACCR; Incidence

1. Introduction

Testicular cancers are rare cancers in the general population, but are the most commonly occurring cancer among men aged 15 to 44 years in the United States [1]. The majority (approximately 98%) of testicular cancers are germ cell tumors (TGCT). TGCTs are classified into three histologic subtypes: seminomas, nonseminomas, and spermatocytic tumors. The median age of diagnosis for seminomas is 35 years and for nonseminomas 25 years while spermatocytic tumors, which are less aggressive and etiologically distinct from seminomas and nonseminomas, peak at an older age (median age 62 years). Seminomas and nonseminomas comprise the majority of germ cell tumors (approximately 56% for seminoma and 43% for nonseminoma) while spermatocytic tumors are much less common, accounting for less than 1% of the total. The small percentage of testicular cancers that are not germ cell tumors (approximately 2%) include sex cord stromal tumors, such as Leydig cell and Sertoli cell tumors, as well as other rare or poorly defined histologic subtypes.

The incidence of TGCT has substantially increased in recent decades [2]. The rapid increase in incidence suggests that critical changes in environmental factors may contribute to the development of TGCT [3]. To date, there are few studies focusing on testicular cancer in men aged 50 years [4,5]. Thus, the aim of this study was to provide detailed descriptive features, including age patterns and incidence rates of TGCT among men aged 50 years. In addition to TGCT, we were also interested in other tumors that arise in the testes, such as primary testicular lymphoma; predominantly a disease of men 50 years and often disregarded in population-based studies.

2. Methods

Primary malignant testicular cancers were identified from the Cancer Incidence in North America (CiNA) analytic file provided by the North American Association of Central Cancer Registries (NAACCR). Cancer incidence data that meet high-quality standards from the SEER program and the Centers for Disease Control and Prevention's National Program of Cancer Registries are included in the CiNA analytic data set [6]. Data from forty-one registries were included for the years 1999 through 2014. These registries included

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, West Virginia, Wisconsin, and Wyoming (approximately 90% coverage of the US population). The CiNA analytic file dates back to 1995, but due to missing data from many of the registries, we restricted all analyses to the year 1999 forward.

Testicular cancers were defined using the International Classification of Diseases for Oncology (3rd ed.) topography (C62) and morphology codes (germ cell tumors: 9060/3–9062/3, 9064/3–9102/3; seminoma: 9060/3–9062/3, 9064/3; nonseminoma: 9065/3–9102/3; spermatocytic tumors: 9063/3; sex cord stromal tumors: 8640/3, 8650/3) [7]. Nonseminomas were further classified as: embryonal carcinoma (9070/3, 9072/3), yolk sac tumors (9071/3), teratoma (9080/3, 9082–9084/3, 9102/3), choriocarcinoma (9100/3, 9101/3), and mixed germ cell tumors (9081/3, 9085/3). Primary testicular lymphomas were identified using a combination of topography (C62) and morphology codes for lymphoma. Incidence rates per 100,000 person-years, age-adjusted to the US 2000 standard population, and their 95% confidence intervals were calculated. Testicular cancer incidence rates were calculated by histologic subtype and age of diagnosis. Estimates of annual percent change (APC) were calculated for the 1999–2014 time period using the annual rates and weighted least squares regression [8]. For temporal analysis, years of diagnosis were grouped into four periods: 1999–2002, 2003–2006, 2007–2010, and 2011–2014. Age of diagnosis was grouped into 8 categories: 50–54 years, 55–59 years, 60–64 years, 65–69 years, 70–74 years, 75–79 years, 80–84 years, and 85+ years. All statistical analyses were performed using the SEER*Stat statistical package (version 8.3.4).

3. Results

Between 1999–2014, 9353 seminomas, 2227 nonseminomas, 533 spermatocytic tumors, 4534 testicular lymphomas, and 288 sex cord stromal tumors were diagnosed among residents of the 41 SEER/NPCR registry areas (Table 1). The percent of tumors that were histologically verified was 99% for all TGCTs (seminomas, nonseminoma, spermatocytic tumors), 97% for testicular lymphomas, and 99% for sex cord stromal tumors.

Of all the tumors, the incidence of nonseminoma increased most notably (APC = 3.26, 95% CI: 2.27–4.25) (Table 1, Fig. 1A). Among nonseminomas, the greatest increase in incidence rates was among mixed germ cell tumors (APC: 4.38, 95% CI: 3.03–5.75) (Table 1).

Incidence rates of seminoma also increased (APC: 1.15, 95% CI: 0.59–1.71), while rates of testicular lymphoma (APC: –0.66, 95% CI: –1.16 to –0.16), spermatocytic tumors (APC: 0.42, 95% CI: –1.42 to 2.29), and sex cord stromal tumors (APC: 0.60, 95% CI: –3.21 to 4.55) remained relatively unchanged throughout the time period (Table 1, Fig. 1A).

Incidence rates of testicular cancer by histologic subtype and age of diagnosis are presented in Supplementary Table 1 and Fig. 1B. The incidence of testicular lymphoma increased from age 50 to age 80–84 years. Among men aged 70 years, lymphoma was the most

commonly occurring cancer in the testis. In contrast, rates of seminoma and nonseminoma declined steadily from the age of 50 years, while the incidence of spermatocytic tumors and sex cord stromal tumors increased steadily. At no age, however, was the incidence of spermatocytic tumors higher than the incidence of seminoma. Sex cord stromal tumors were the most uncommon tumor type at all ages.

Incidence rates of testicular cancer by race/ethnicity are presented in Table 2. Non-Hispanic white men had the highest rates of TGCT overall (rate: 2.14, 95% CI: 2.10–2.18), followed by Hispanic (rate: 0.98, 95% CI: 0.89–1.07), Asian/Pacific Islander (rate: 0.60, 95% CI: 0.51–0.70), and non-Hispanic black men (rate: 0.50, 95% CI: 0.44–0.56). The same rankings were similar for all TGCT histological subtypes (seminoma, nonseminoma, spermatocytic tumors) with higher rates among Non-Hispanic whites and Hispanics than among Non-Hispanic blacks and Asian/Pacific Islanders. The incidence of testicular lymphomas was also highest among non-Hispanic white men (rate: 0.80, 95% CI: 0.77–0.82), followed by Asian/Pacific Islander (rate: 0.72, 95% CI: 0.62–0.84), Hispanic (rate: 0.71, 95% CI: 0.63–0.80), and non-Hispanic black men (rate: 0.24, 95% CI: 0.20–0.29). Among sex cord stromal tumors, the incidence was highest among non-Hispanic black men (rate: 0.07, 95% CI: 0.05–0.10), followed by non-Hispanic white (rate: 0.05, 95% CI: 0.04–0.05), Hispanic (rate: 0.04, 95% CI: 0.03–0.07), and Asian/Pacific Islander men (rate: 0.01, 95% CI: 0.01–0.06).

4. Discussion

During the time period 1999–2014, incidence rates of nonseminoma among men of ages 50 and greater, increased more notably than incidence rates of other tumors arising in the testis. Incidence rates of seminoma also increased, while rates of spermatocytic tumors, testicular lymphomas, and sex cord stromal tumors remained relatively unchanged throughout the time period. The examination of age-specific rates revealed that the incidence of spermatocytic tumors, sex cord stromal tumors, and testicular lymphoma increased steadily with age in contrast to rates of seminoma and nonseminoma, which steadily declined with age.

The current study found that testicular lymphoma is the most commonly occurring testicular malignancy among men aged 70 years. Primary testicular lymphoma is a rare, clinically aggressive form of extranodal non-Hodgkin lymphoma (NHL) accounting for < 5% of testicular cancers. The vast majority of cases are classified as histologically diffuse large B-cell lymphoma with high bilateral testicular involvement. There are limited data regarding specific risk factors for testicular lymphoma, however, human immunodeficiency virus (HIV) infection is a known risk factor for NHL, with lymphomas in HIV-infected patients presenting more commonly with extranodal primary sites, including the testis [9].

The current study also found that the age-specific rates of spermatocytic tumors and sex-cord stromal tumors increased steadily with age in contrast to rates of seminoma and nonseminoma. Spermatocytic tumors, formerly called spermatocytic seminomas, are relatively indolent tumors that rarely metastasize and do not merit treatment apart from orchiectomy [10]. Even though the highest rates of spermatocytic tumors occur among men 50 years, the incidence of spermatocytic tumors is always less than the incidence of

seminoma, regardless of age. Sex-cord stromal tumors are extremely rare (approximately 2% of testicular cancer) and can appear sporadically or in combination with hereditary syndromes, such as Peutz–Jeghers syndrome [11]. The etiology of sex cord stromal tumors is poorly understood, although associations with fumarate hydratase (FH) mutations, Klinefelter syndrome, hereditary leiomyomatosis, and renal cell carcinoma have been reported [12]. Finally, the current study found an increase in the incidence of mixed germ cell tumors (MGCT) during the study period. Whether the increase reflects a true change in incidence is unclear, however, as the morphology code for MGCT was introduced with the release of ICDO-3 in 2001, thus, it is possible that the observed increase in MGCT is simply due to the more frequent usage of the MCGT specific code over time.

There is a notable difference in TGCT risk among different racial/ ethnic groups in the US. Non-Hispanic white men have the highest incidence rates of TGCT while non-Hispanic black men have the lowest. In contrast to TGCT incidence rates, the present study found that incidence rates of sex-cord stromal tumors and testicular lymphomas do not vary greatly by race/ethnicity.

Genetic susceptibility to TGCT exists, as evidenced by findings from genome wide association studies (GWAS). GWAS studies have identified at least 39 loci associated with TGCT susceptibility [13–19]. Genetic factors, however, cannot solely explain the steady increases observed in TGCT rates since the mid-20th century. Rather, increases in one or more environmental risk factors or decreases in protective factors are likely leading to the increasing incidence among genetically susceptible men.

The exact number of mutations that must occur to transform a normal human cell into a tumor cell is unknown. By constructing a mathematical model based upon the multi-hit hypothesis and comparing it to age-specific incidence data, Brody was able to show that type II TGCTs occur after four mutations [20]. This further implies that type II TGCTs are genetically or epigenetically predetermined at an early age or before birth and supports the prevailing Testicular Dysgenesis Syndrome hypothesis concerning the etiology of TGCTs, that risk is largely determined in-utero [21] and that perinatal risk factors may be most relevant. It is unclear, however, whether the etiology of the type II TGCTs is the same among men under 50 and men ≥ 50 years because few studies have included men ≥ 50 years. It is conceivable however, that all type II TGCTs are initiated in-utero, but a small percentage of men do not have another “insult,” either genetic or environmental, until they are in their 6th, 7th, or 8th decade of life [20].

A strength of the current study was the use of population-based cancer registry data from 41 registries, which captured a large percentage of the US population. Limitations include the inability to examine incidence rates among American Indian/Alaska Native populations because of small case counts. The current study lacked information on place of birth and country-specific ancestry, which may be useful in examining hypotheses concerning environmental and genetic risk factors of TGCT. An additional limitation was the use of the NHIA algorithm for the identification of Hispanic ethnicity, because this could result in potential misclassification; however males are arguably less likely to be incorrectly classified.

In conclusion, given the distinct time-trends and age-specific patterns of testicular cancer in men aged 50 years and older, additional investigation of risk factors for these tumors is warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by the intramural research programs of the National Cancer Institute (NCI). Additionally, this work was supported by grants of Wilhelm-Roux-Program of Medical Faculty, Martin-Luther-University of Halle-Wittenberg (grant number 27/38) and a grant from the German Federal Ministry of Education and Science (BMBF) (grant number 01ER1305).

References

- [1]. Ghazarian AA, Trabert B, Devesa SS, McGlynn KA, Recent trends in the incidence of testicular germ cell tumors in the United States, *Andrology* 3 (1) (2015) 13–18. [PubMed: 25331158]
- [2]. Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA, International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007, *Andrology* 3 (1) (2015) 4–12. [PubMed: 25331326]
- [3]. Horwich A, Shipley J, Huddart R, Testicular germ-cell cancer, *Lancet* (Lond. Engl.) 367 (9512) (2006) 754–765.
- [4]. Wheeler MJ, Manners J, Nolan L, Simmonds PD, Hayes MC, Mead GM, The clinical features and management of testicular germ cell tumours in patients aged 60 years and older, *BJU Int.* 108 (11) (2011) 1794–1799. [PubMed: 21627751]
- [5]. Feldman DR, Voss MH, Jacobsen EP, Jia X, Suarez JA, Turkula S, Sheinfeld J, Bosl GJ, Motzer RJ, Patil S, Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older, *Cancer* 119 (14) (2013) 2574–2581. [PubMed: 23606402]
- [6]. Tucker TC, Howe HL, Measuring the quality of population-based cancer registries: the NAACCR perspective, *J. Reg Manage* 28 (2001) 41–44.
- [7]. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin MD (Eds.), *International Classification of Diseases for Oncology (ICD-O)*, 3rd ed., World Health Organization, Geneva, 2000.
- [8]. Kim HJ, Fay MP, Feuer EJ, Midthune DN, Permutation tests for joinpoint regression with applications to cancer rates, *Stat. Med* 19 (3) (2000) 335–351. [PubMed: 10649300]
- [9]. Cheah CY, Wirth A, Seymour JF, Primary testicular lymphoma, *Blood* 123 (4) (2014) 486–493. [PubMed: 24282217]
- [10]. Ulbright TM, Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues, *Mod. Pathol* 18 (Suppl. (2)) (2005) S61–S79. [PubMed: 15761467]
- [11]. Young RH, Sex cord stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems, *Mod. Pathol* 18 (Suppl. (2)) (2005) S81–S98. [PubMed: 15502809]
- [12]. Idrees MT, Ulbright TM, Oliva E, Young RH, Montironi R, Egevad L, Berney D, Srigley JR, Epstein JI, Tickoo SK, The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel, *Histopathology* 70 (4) (2017) 513–521. [PubMed: 27801954]
- [13]. Ruark E, Seal S, McDonald H, Zhang F, Elliot A, Lau K, Perdeaux E, Rapley E, Eeles R, Peto J, Kote-Jarai Z, Muir K, Nsengimana J, Shipley J, Bishop DT, Stratton MR, Easton DF, Huddart RA, Rahman N, Turnbull C, Identification of nine new susceptibility loci for testicular cancer,

including variants near DAZL and PRDM14, Nat. Genet 45 (6) (2013) 686–689. [PubMed: 23666240]

- [14]. Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S, Morrison J, Nsengimana J, Deloukas P, Rahman N, Bishop DT, Easton DF, Stratton MR, A genome-wide association study of testicular germ cell tumor, Nat. Genet 41 (7) (2009) 807–810. [PubMed: 19483681]
- [15]. Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J, Albano A, Chen C, Starr JR, Rader DJ, Godwin AK, Reilly MP, Hakonarson H, Schwartz SM, Nathanson KL, Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer, Nat. Genet 41 (7) (2009) 811–815. [PubMed: 19483682]
- [16]. Chung CC, Kanetsky PA, Wang Z, Hildebrandt MA, Koster R, Skotheim RI, Kratz CP, Turnbull C, Cortessis VK, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fossa SD, Jacobs KB, Korde LA, Kraggerud SM, Lothe RA, Loud JT, Rahman N, Skinner EC, Thomas DC, Wu X, Yeager M, Schumacher FR, Greene MH, Schwartz SM, McGlynn KA, Chanock SJ, Nathanson KL, Meta-analysis identifies four new loci associated with testicular germ cell tumor, Nat. Genet 45 (6) (2013) 680–685. [PubMed: 23666239]
- [17]. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, Huddart RA, Bishop DT, Easton DF, Stratton MR, Rahman N, Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer, Nat. Genet 42 (7) (2010) 604–607. [PubMed: 20543847]
- [18]. Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MA, Kratz CP, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fossa SD, Greene MH, Jacobs KB, Kanetsky PA, Kolonel LN, Loud JT, Korde LA, Le Marchand L, Lewinger JP, Lothe RA, Pike MC, Rahman N, Rubertone MV, Schwartz SM, Siegmund KD, Skinner EC, Turnbull C, Van Den Berg DJ, Wu X, Yeager M, Nathanson KL, Chanock SJ, Cortessis VK, McGlynn KA, Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23, Hum. Mol. Genet 22 (13) (2013) 2748–2753. [PubMed: 23462292]
- [19]. Wang Z, McGlynn KA, Rajpert-De Meyts E, Bishop DT, Chung CC, Dalgaard MD, Greene MH, Gupta R, Grotmol T, Haugen TB, Karlsson R, Litchfield K, Mitra N, Nielsen K, Pyle LC, Schwartz SM, Thorsson V, Vardhanabhuti S, Wiklund F, Turnbull C, Chanock SJ, Kanetsky PA, Nathanson KL, Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor, Nat. Genet 49 (7) (2017) 1141–1147. [PubMed: 28604732]
- [20]. Brody JP, Age-specific incidence data indicate four mutations are required for human testicular cancers, PloS One 6 (10) (2011) e25978. [PubMed: 21998737]
- [21]. Skakkebaek NE, Rajpert-De Meyts E, Main KM, Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects, Hum. Reprod. (Oxf. Engl.) 16 (5) (2001) 972–978.

Fig. 1. Age-adjusted incidence rates of testicular cancer by histologic subtype and (a) year of diagnosis, (b) age of diagnosis, SEER/NPCR registries, 1999–2014.

Table 1

Age-standardized incidence rates of testicular cancer by histologic subtype among men aged 50 years, SEER/NPCR Registries, 1999–2014.

	Count	Rate (95% CI) ^a	APC (95% CI)
Seminoma	9353	1.46 (1.43–1.49)	1.15 (0.59–1.71)
Nonseminoma	2227	0.35 (0.33–0.36)	3.26 (2.27–4.25)
Embryonal carcinoma	426	0.07 (0.06–0.07)	–0.24 (–2.17 to 1.72)
Yolk sac tumors	92	0.01 (0.01–0.02)	<i>b</i>
Teratoma	87	0.01 (0.01–0.02)	2.25 (–1.64 to 6.29)
Choriocarcinoma	131	0.02 (0.02–0.02)	0.29 (–3.34 to 4.06)
Mixed germ cell tumors	1,339	0.21 (0.20–0.22)	4.38 (3.03–5.75)
Spermatocytic tumors	533	0.09 (0.09–0.10)	0.42 (–1.42 to 2.29)
Testicular lymphomas	4534	0.75 (0.72–0.77)	–0.66 (–1.16 to –0.16)
Sex cord stromal tumors	288	0.05 (0.04–0.05)	0.60 (–3.21 to 4.55)

APC = Annual Percent Change.

CI = Confidence Interval.

^aRates are per 100,000 and age-adjusted to the 2000 US Standard Population.

^bThe APC could not be calculated.

Table 2

Age-standardized incidence rates of testicular cancer by race/ethnicity, SEER/NPCR Registries, 1999–2014.

	Non-Hispanic White		Hispanic (All Races)		Non-Hispanic Black		Asian/Pacific Islander	
	Count ^a	Rate (95% CI) ^b	Count ^a	Rate (95% CI) ^b	Count ^a	Rate (95% CI) ^b	Count ^a	Rate (95% CI) ^b
Seminoma	8,391	1.73 (1.69–1.77)	454	0.78 (0.71–0.86)	246	0.39 (0.34–0.44)	138	0.50 (0.42–0.60)
Nonseminoma	1,999	0.41 (0.39–0.43)	109	0.19 (0.16–0.24)	70	0.11 (0.09–0.15)	27	0.10 (0.06–0.15)
Spermatocytic tumors	478	0.11 (0.10–0.12)	27	0.06 (0.04–0.10)	19	0.04 (0.02–0.06)	C	0.01 (0.00–0.05)
Testicular lymphoma	3,863	0.80 (0.77–0.82)	311	0.71 (0.63–0.80)	131	0.24 (0.20–0.29)	194	0.72 (0.62–0.84)
Sex cord stromal tumors	217	0.05 (0.04–0.05)	19	0.04 (0.03–0.07)	41	0.07 (0.05–0.10)	C	0.01 (0.01–0.06)

CI = Confidence Interval.

^aMay not sum to total because of missing race.

^bRates are per 100,000 and age-standardized to the 2000 US Standard Population.

^cCase counts less than 15.